This article from the American College of Physicians (ACP) provides a deeper dive into the pause of the J&J vaccine, which was recommended by the FDA and CDC on April 13, 2021, after six cases of cerebral venous sinus thrombosis (CVST) among patients who had received the vaccine was reported. The pause is being done […]
These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of von Willebrand Disease (VWD), a common inherited bleeding disorder.
In this symposium preceding the ASH Annual Meeting on 12/4/20, the overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. The speakers will illustrate how costly and unnecessary biochemical, phenotypic, and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.
In this “How I Treat” feature from Blood, the authors conclude with three representative cases to both illustrate the application of the outlined diagnostic schema and discuss common management considerations, specifically the selection of anticoagulation vs. antiplatelet therapy for secondary prevention.